Edelweiss Evrard
Pfizer (United States)(US)
Publications by Year
Research Areas
Computational Drug Discovery Methods, Chemical Synthesis and Analysis, Receptor Mechanisms and Signaling, Tryptophan and brain disorders, Synthesis and Catalytic Reactions
Most-Cited Works
- → Introduction of a Crystalline, Shelf-Stable Reagent for the Synthesis of Sulfur(VI) Fluorides(2018)136 cited
- → Discovery of Brain-Penetrant, Irreversible Kynurenine Aminotransferase II Inhibitors for Schizophrenia(2012)89 cited
- → Discovery of 4-(5-Methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a Novel α7 Nicotinic Acetylcholine Receptor Agonist for the Treatment of Cognitive Disorders in Schizophrenia: Synthesis, SAR Development, and in Vivo Efficacy in Cognition Models(2009)74 cited
- → PF-04859989 as a template for structure-based drug design: Identification of new pyrazole series of irreversible KAT II inhibitors with improved lipophilic efficiency(2013)31 cited
- → Photoaffinity Labeling and Quantitative Chemical Proteomics Identify LXRβ as the Functional Target of Enhancers of Astrocytic apoE(2020)27 cited
- → Structure-Based Design of Irreversible Human KAT II Inhibitors: Discovery of New Potency-Enhancing Interactions(2012)23 cited
- → A General Strategy for the Synthesis of Cyclic N-Aryl Hydroxamic Acids via Partial Nitro Group Reduction(2011)21 cited
- → Discovery of hydroxamate bioisosteres as KAT II inhibitors with improved oral bioavailability and pharmacokinetics(2012)20 cited
- → Discovery of indole-derived pyridopyrazine-1,6-dione γ-secretase modulators that target presenilin(2014)19 cited
- → Discovery of cyclopropyl chromane-derived pyridopyrazine-1,6-dione γ-secretase modulators with robust central efficacy(2016)17 cited